Abstract

On June 2, Indivior, which makes the buprenorphine product Suboxone, resolved a lawsuit by 42 attorneys general (AGs)who had claimed that the Virginia‐based pharmaceutical company fraudulently removed its tablets from the market in order to prevent generics from entering. In the agreement, announced June 2, Indivior will pay the states a total of $102.5 million.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call